BOC Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's revenue side performance is growing steadily, and the gross margin of the pharmaceutical sector business is under downward pressure in 2023; 2) Actively strengthening the medical and aesthetic layout, and the medical and aesthetic business approved by AestheFill can be expected in the future. (Mainichi Keizai Shimbun)
中银证券4月26日发布研报称，给予江苏吴中（600200.SH）买入评级。评级理由主要包括：1）公司收入端业绩增长稳健，医药板块业务 2023 年毛利率受到下行压力；2）积极加强医美布局，AestheFill 获批医美业务未来可期。（每日经济新闻）
BOC Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's revenue side performance is growing steadily, and the gross margin of the pharm
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated